Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer- United States

doi 10.1016/j.clbc.2012.11.007

Full Text

Abstract

Available in

Categories

Cancer Research

Date

April 1, 2013

Authors

Rodrigo Santa Cruz Guindalini

Galina Khramtsova

Olufunmilayo I. Olopade

Publisher

Elsevier BV

Related search

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer

Cancer Research

English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Cancer Research

English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer

Cancer Research

English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research

English

Invasive Mucinous Carcinoma of the Breast

Baylor University Medical Center Proceedings

English

PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?

Breast Cancer Research

Cancer Research

English

The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma in Situ to Invasive Carcinoma of the Breast

Modern Pathology

Forensic Medicine

English

Identification of Aberrant Gene Expression During Breast Ductal Carcinoma in Situ Progression to Invasive Ductal Carcinoma

Journal of International Medical Research

English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine

English